{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-103058","form_type":"8-K","ticker":"ADPT","cik":"0001478320","company_name":"Adaptive Biotechnologies Corp","filed_at":"2025-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.076001+00:00","generated_at":"2026-05-17T20:36:44.459203+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Adaptive Q2 MRD revenue up 42%, achieves MRD profitability; raises FY guidance","bullets":["Total revenue $58.9M (+36% YoY); MRD revenue $49.9M (+42% YoY); MRD Adjusted EBITDA positive $1.9M.","clonoSEQ volume 25,321 (+37% YoY); Immune Medicine revenue $8.9M (+13% YoY).","Net loss $25.6M ($46.2M in Q2 2024); Adjusted EBITDA loss $7.2M vs $21.4M prior year.","FY 2025 MRD revenue guidance raised to $190-200M (from $180-190M); cash burn guidance lowered to $45-55M.","Cash $222M; launched clonoSEQ integration into Flatiron OncoEMR; recognized $5.5M pharma milestone revenue."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-103058","json":"https://secwatch.observer/filing/0000950170-25-103058.json","markdown":"https://secwatch.observer/filing/0000950170-25-103058.md","text":"https://secwatch.observer/filing/0000950170-25-103058.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1478320/000095017025103058/0000950170-25-103058-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1478320/000095017025103058/adpt-20250805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T20:36:44.459203+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}